News Archives - Page 10 of 11 - Buhlmann Diagnostics Corp

Category: News

BUHLMANN LabSense News: Winter 2017 Edition

BUHLMANN Diagnostics Corp is proud to release the second edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News.  Here you will also be able to access valuable resources, applications, and other newsworthy items specific to fields of in vitro diagnostics and scientific research. In this edition we
Continue Reading

Quantum Blue® Infliximab Assay Highlights

US: BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US. Not to be used in diagnostic procedures. Canada: BÜHLMANN Quantum Blue® Infliximab: Health Canada License: 98838 Rapid, Simple, Accurate Quantitative Results BÜHLMANN’s Quantum Blue® Product line is designed with an innovative solution based on established lateral flow technology which utilizes highly specific monoclonal antibodies to capture
Continue Reading

Connect with BUHLMANN Diagnostics Corp at CDDW 2017

Canadian Digestive Diseases Week (CDDW) 2017 BUHLMANN Diagnostics Corp Booth: #1032 Mar 03 – 06, 2017 LOCATION The Fairmont Banff Springs Banff, Alberta LEARN MORE Click & Contact CDDW 2017 BUHLMANN Team Connect with our team ahead of time, learn more about our Calprotectin Assays or schedule a meeting! COLLIN SHAW VP of Business Development
Continue Reading

Basophil Activation Testing – Standardized

3 Reasons to Consider this Method in Kinase Inhibitor Drug Development Basophils are the circulating immune cells that participate in allergic reactions and share many of the signaling pathways that are also present in other types of immune cells that may develop into blood cancers or participate in the development of autoimmune disorders.  Therefore, measuring
Continue Reading

Safe Use of Stool Extracts on Clinical Chemistry Analyzers

BÜHLMANN fCAL® turbo is for Research Use Only. Not to be used in diagnostic procedures. Health Canada License: 96808 BÜHLMANN fCAL® turbo Stool extracts used in the BÜHLMANN fCAL® turbo on clinical chemistry analyzers can be applied without any concern of system contamination. BÜHLMANN investigated this new sample matrix with the goal to exclude potential risks.
Continue Reading

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory BowelDisease Can J Gastroenterol Hepatol. 2016;2016:2483261. Epub 2016 Sep 28.DOI:10.1155/2016/2483261.  PMID: 27774443.  This Canadian study represents how FCAL testing is utilized in the field for monitoring disease activity in IBD.  The reference for the cut-off
Continue Reading

Evaluation of the BÜHLMANN fCAL® turbo Test at Bioanalytica Lucerne

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 French Version Interview with Yvonne Schallberger, Bioanalytica Lucerne Mrs. Schallberger, you recently decided to introduce the new calprotectin assay, BÜHLMANN fCAL® turbo, which offers a calprotectin result in random access mode on all USUAL
Continue Reading

BUHLMANN Highlights – ACE Kinetic Enzymatic Assay

BÜHLMANN ACE Kinetic Enzymatic Assay Simple, Fast, Versatile Automated Assay for use on Multiple Clinical Chemistry Platforms ACE kinetic is FDA 510(k) cleared. For in vitro Diagnostic Use. BÜHLMANN's Clinical Chemistry product line is a unique selection of high quality assays for routine and specialized testing in clinical chemistry.  Employing the long lasting experience with ACE activity on
Continue Reading

BUHLMANN Flow CAST Kinase Inhibition Assay and Utilization in Research

BÜHLMANN's Kinase Inhibition Assay has been utilized in several publications in various fields of study such as drug discovery, cancer research, autoimmune disease research, and more. Several key kinases that are molecular targets in drug discovery, such as PI3Kγ and PI3Kδ, SYK, BTK are main components in the basophil activation signaling pathways. Our Assay  has been
Continue Reading

Proactive Therapeutic Drug Monitoring of Infliximab: A Comparative Study of a New Point-of-Care Quantitative Test with Two Established ELISA Assays

BÜHLMANN Quantum Blue® Infliximab Trough Level Assay Citation: Afonso J, Lopes S et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. PMID: 27507790 First Publication using our Quantum Blue® Infliximab Trough Level Assay We are very
Continue Reading